Collegium Pharmaceutical, Inc.: stock overview

COLLNASDAQHealthcare · Pharmaceutical Preparations

Price

$25.32

November 13, 2026Market cap $804M

DCF calculator

What Ploutos Investor adds for Collegium Pharmaceutical

Part of Ploutos Investor, €9.99 a month

See the plans
  • The full history: 10 fiscal years, from 2016
  • The estimated fair value, with its range and its certainty
  • The full analysis, 18 a month
  • More questions to the chat on its filings
  • Excel with every year
  • An email when it reports, changes its dividend or an officer buys

Sign in with a free account to see the last 5 fiscal years.

Notes on these figures

  • The interest the company pays is far more than the debt we can read would cost, so part of its borrowing is missing from the figures. We leave out the debt, net cash, enterprise value and the multiples built on them.
  • Earnings per share here are the last twelve months' earnings over today's shares, so they agree with the P/E. The number of shares changed a lot during the year, so they differ from the earnings per share the company filed, which use the year's average number of shares.

In short

Collegium Pharmaceutical had revenue of $815M over the last 12 months and net income of $38M, a net margin of 4.7%. Revenue grew by 20.3% a year on average over the last 5 years. At $25.32 the shares trade at a P/E of 21.1, against a median of 19.6 over the last 4 fiscal years. It pays no dividend.

From its SEC filings (latest fiscal year to December 31, 2025) and the price of November 13, 2026.

Its SEC filings
Market cap
$804M
31.75M shares
P/E
21.1
Today21.1
Median19.6
Revenue, 12 months
$815M
+20.3% a year over 5 years
Net margin
4.7%
2025: 8.1%, above 71% of its industry

Worth knowing

What a holder would want to hear from the company's SEC filings of the last three years. Each with its filing, without comment.

3 fiscal years in figures

Each fiscal year's figures as the company filed them, and the share price at its end.

2023–2025 fiscal years

+17.4% a year over 2 years

  • 202510-K
    Revenue$781M
  • 202410-K
    Revenue$631M
  • 202310-K
    Revenue$567M

Fiscal years in figures

COLL's revenue, profit, cash flow and dividend with each year-end price, from 2016 to 2022, 7 more fiscal years

Part of Ploutos Investor, €9.99 a month

See the plans

Sign in with a free account to see the last 5 fiscal years.

Key figures

The company's current figures in five groups. Each term is explained behind its ⓘ.

Valuation

Market cap 3-year median: $984M
$804M
Enterprise value 
–
P/E 3-year median: 23.9
21.1
EV / EBIT 
–
EV / Revenue 
–
P/B 3-year median: 4.9
2.7
FCF yield 3-year median: 22.5%
41.8%
Earnings yield 3-year median: 4.2%
4.8%

Profitability

Gross margin 
59.1%
Operating margin 
15.2%
Net margin 3-year median: 8.5%
4.7%
ROIC 
19.2%
ROIC, 5-year average 
15.9%
ROE 
12.8%

Growth

Revenue, yearly change 
+23.6%
EPS, yearly change 
-7.0%
FCF, yearly change 
+61.1%
Revenue, average a year 
+20.3%
EPS, average a year 
+17.9%

The yearly change compares FY2025 with FY2024.

Balance sheet

Cash 
$145M
Total debt 
–
Net cash 
–
Net debt / EBITDA 
–
Interest cover 
1.6x
Current ratio 
1.01

Balance sheet of September 30, 2026.

Returns to shareholders

Dividend yield 
0.00%
Buybacks 
3.12%
Total returned 
3.12%
Shares, yearly change 
+0.9%
Valuation against its own pastEach fiscal year's P/E, P/FCF and P/B beside today's, and the DCF calculator for the company.Valuation

Against its industry

Where its margins and returns stood in fiscal 2025 among the SEC filers of its industry (SIC code 28).

Gross margin

59.4%

Above 70% of the 141 companies in its industry, and 77% of all.

Operating margin

23.0%

Above 88% of the 285 companies in its industry, and 86% of all.

Net margin

8.1%

Above 71% of the 302 companies in its industry, and 61% of all.

ROE

20.9%

Above 81% of the 267 companies in its industry, and 85% of all.

ROA

3.8%

Above 68% of the 313 companies in its industry, and 66% of all.

Revenue growth

23.6%

Above 76% of the 292 companies in its industry, and 85% of all.

From the yearly figures every company files with the SEC, for those with revenue of at least $25 million. The industry is the first two digits of the SIC code.

The company at the SEC

How it is registered and when its fiscal year ends.

Name at the SEC
COLLEGIUM PHARMACEUTICAL, INC
CIK
1267565
Exchange
NASDAQ
Industry (SIC)
2834 · Pharmaceutical Preparations
Fiscal year ends
December 31
Latest annual report
December 31, 2025
Reporting currency
USD
Shares
31.75M

Other companies: Healthcare

The largest companies of the same sector, each with its own page.

The Healthcare sectorAll companies

The full analysis

What do Collegium Pharmaceutical's filings show?

These are Collegium Pharmaceutical's figures. The full Ploutos AI analysis reads everything the company has filed and shows what stands behind it, with a source for every figure.

  • A fair value range built from the filings
  • Earnings quality, debt and red flags
  • Insider and institutional moves
  • The case for and the case against

Questions about COLL

Didn't find what you were looking for?

Ask us
What is COLL's market cap?

Collegium Pharmaceutical, Inc.'s market cap is $804M, at a price of $25.32 on November 13, 2026 and 31.75M shares.

What is COLL's P/E?

COLL's P/E is 21.1, on earnings per share of $1.20 over the last 12 months. The median over the last 4 fiscal years was 19.6.

How much revenue does COLL have?

Collegium Pharmaceutical had revenue of $815M over the last 12 months. Over the last 5 years it changed by +20.3% a year on average.

Does COLL pay a dividend?

No. Collegium Pharmaceutical paid no regular dividend over the last 12 months.

Where do the figures come from?

From Collegium Pharmaceutical, Inc.'s SEC filings (10-K and 10-Q) and the share price. They hold no analyst estimates and no score, and they are not a recommendation.

Related pages

The other pages on US stocks, free to read. On the company pages, the last three fiscal years are open to everyone, five with a free account, and every year with Ploutos Investor.

US stocksThe market today, the sectors, the largest companies and the week's results.The market's sectorsThe 11 sectors side by side: returns, share of the market, median P/E and dividend.Compare stocksTwo companies side by side: price over up to ten years, with and without dividends, and every figure.US dividend stocksEach dividend's yield next to whether the company's cash covers it and whether it was ever cut.

The figures come from the company's SEC filings and the share price, and describe what it has reported. They are not a score or a fair value.